| Today's Big NewsAug 2, 2023 |
|
Wednesday, September 6, 2023 | 2:00 PM ET / 11:00 AM PT Attendees will learn about the latest tools for interacting with medical images, how to guide readers through labeling workflows, and streamlining adjudication and data standardization. Discussions will include real-world use cases of how pharma companies are enhancing AI development by optimizing reader workflows. Register now.
|
|
| By Fraiser Kansteiner Teva has long maintained its innocence in the face of a far-reaching price-fixing indictment by the U.S. Department of Justice. Now, the company is earmarking a sizeable chunk of cash in an attempt to put the charges to bed. |
|
|
|
By Gabrielle Masson Moderna's buzzy cancer vaccine partnership with Merck will soon take a leap into lung cancer, after recent clinical data showed the shot—alongside Merck's blockbuster Keytruda—significantly reduced risk of recurrence or death in patients with melanoma. |
By Conor Hale In February, Abbott and the FDA notified clinicians that studies pointed toward higher rates of aortic valve implant failures in the first five years. |
By Annalee Armstrong We take protecting anonymous sources around here seriously. So when we do use one, you know the subject is important. Fierce Biotech tracked down the Twitter/X biotech meme over lord/lady Goose Data. |
|
Thursday, August 3, 2023 | 11am ET / 8am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now.
|
|
By Fraiser Kansteiner GSK says Pfizer’s vaccine RSV vaccine Abrysvo—approved in late May—infringes four patents related to its RSV antigen shot Arexvy, which itself snagged a green light in the U.S. earlier that same month. |
By Conor Hale While a long-expected decline in COVID-19 antigen diagnostics also took a bite out of Siemens’ numbers, the company attributed the recent shrinkage in Varian’s profit margin to external factors such as inflation and ongoing kinks in the supply chain. |
By Annalee Armstrong Early-stage investments in biopharma are up this year, but valuations have come way down. investors are looking for proven leadership teams and an exit strategy that does not involve waiting for the IPO window to magically open up, according to a new H1 analysis by Silicon Valley Bank. |
By Nick Paul Taylor CG Oncology has raised the rarely seen crossover round. Once ubiquitous, the pre-IPO rounds have dried up in the biotech bear market—but CG’s fully enrolled phase 3 bladder cancer clinical trial has persuaded investors to dig out their checkbooks and pump $105 million into the business. |
By Kevin Dunleavy With sales of its lone approved product stagnating, Karyopharm Therapeutics has reduced its workforce by 20%, the company said on Wednesday. The reduction includes full-time employees and contractors. The cuts extend Karyopharm’s cash runway into late 2025. |
By Conor Hale With the upcoming winter season, BD aims to provide a molecular panel that screens for COVID-19, respiratory syncytial virus and influenza A and B using a single swab. |
By Nick Paul Taylor Surface Oncology has shown investors the ghost of biotech yet to come. Needing shareholder support for its planned merger with Coherus BioSciences, the biotech has told investors that outlays triggered by the deal have shrunk its cash runway and will leave it needing funding fast if the deal collapses. |
By Zoey Becker The company brought the slow-release schizophrenia med Uzedy and an extended-release version of Austedo to the market this quarter. After reporting second-quarter results, Teva narrowed its full-year revenue outlook to a new range of $15 billion to $15.4 billion. |
By Andrea Park With platelet-specific donations expected to fall well short of U.S. demand, the FDA has greenlighted a solution: a machine from Terumo that can separate out platelets and other components from previously collected whole-blood samples rather than relying on real-time procedures. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss the chemotherapy drug shortage, plus Grail’s harassment lawsuit and the rest of this week’s headlines |
|
|---|
|
|
|
Wednesday, August 30, 2023 | 1pm ET/ 10am PT Enzymes have long demonstrated their utility as a green alternative to metal-based catalysts, but the evolution time required can be significant. Join this webinar to learn about an extracellular strategy that reduces the evolution cycle and enables biocatalysis to be used much earlier in development. Register now.
|
|
| WhitepaperIn oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperLeading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| ResearchLearn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WebinarDownload this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
| WhitepaperLearn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
| |
|
